st266
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02761993)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- st266
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06315738 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2024 | Noveome Biotherapeutics, Parexel |
| NCT05066698 | Phase 2 | Oct 13, 2021 | IQVIA, Noveome Biotherapeutics |
| NCT04720378 | Phase 1 | May 30, 2021 | IQVIA, Noveome Biotherapeutics |
| NCT03901781 | Phase 1 | Jun 1, 2019 | Noveome Biotherapeutics |
| NCT03687632 | Phase 2 | Oct 31, 2018 | Noveome Biotherapeutics |
| NCT02978183 | Phase 2 | Dec 1, 2016 | Noveome Biotherapeutics |
| NCT02761993 | Phase 2 | Apr 1, 2016 | Noveome Biotherapeutics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Noveome Biotherapeutics | For profit | 7 | 7 | 2 | 2016 |
| IQVIA | For profit | 2 | 0 | 2 | 2021 |
| Parexel | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1